Promising outlook for frontline blinatumomab in Ph+ ALL

Promising outlook for frontline blinatumomab in Ph+ ALL

User Photo
VJHemOnc

2 years
138 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Acute lymphoblastic leukemia (ALL) is currently treated with a regimen of drugs that, while effective to an extent, could be improved upon. In this interview, Giovanni Martinelli, MD, of the Istituto Scientifico Romagnolo, Meldola, Italy, talks about a recently developed drug, blinatumomab. While the data from the current clinical trial, D-ALBA (NCT02744768), has only recently become available, Prof. Martinelli is hopeful enfor this treatment. This interview took place at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden.
Up Next Autoplay